Journal article

Human biodistribution and internal dosimetry of 4-[F-18]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart

Cameron D Pain, Graeme J O'Keefe, Uwe Ackermann, Vincent Dore, Victor L Villemagne, Christopher C Rowe

EJNMMI Research | SPRINGER | Published : 2020

Abstract

BACKGROUND: 4-[18F] fluorobenzyl dexetimide (F-DEX) is the first non-subtype selective fluorine-18 labelled tracer for muscarinic receptors (mAChR) used in humans. A recent first-in-human study found high regional brain uptake with low variation in normal subjects. Disturbance of mAChR has been reported in Alzheimer's and Parkinson's disease, schizophrenia and depression and various cardiac diseases. The following work assesses the biodistribution, organ tracer kinetics and radiation dose associated with F-DEX. METHOD: Dose calculations were based on activity uptake derived from multiple time point whole body PET CT imaging and the organ-specific dosimetric S-factors derived from the ICRP 13..

View full abstract